May 1, 1990Critical Care Medicine

Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension

View Full Paper

Ask AI

Bookmark

Why the study?

Does intravenous fenoldopam mesylate reduce blood pressure in patients with severe systemic hypertension?

Population

14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg)

Design

Cohort, open-label

Follow-up

≥8 hours

Authors

MMMark A. MungerUniversity of Utah WRWilliam F. RutherfordLouisiana State University LALynn AndersonCambridge Health Alliance

Discussion

Member takes

Implication

May support fenoldopam for acute BP control in severe hypertension; leaves open confirmation by randomized trials.

Structured PICO

Does intravenous fenoldopam mesylate reduce blood pressure in patients with severe systemic hypertension?

Population

14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg)

Intervention

Intravenous fenoldopam mesylate (initial infusion rate 0.1 microgram/kg.min, titrated to diastolic BP goal of 95 to 110 mm Hg, followed by constant infusion for ≥6 h, detitration for 2 h, and postinfusion phase)

Outcome

Acute blood pressure responsesurrogate

Intravenous fenoldopam mesylate is an effective and well-tolerated agent for acute blood pressure reduction in patients with severe hypertension.

Cite This Study

Munger et al. (1990) studied this question.

synapsesocial.com/papers/6a70a9d8a528af2d65c3aa65 https://doi.org/10.1097/00003246-199005000-00008

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider